Skip to main content
. 2021 May 14;13(10):2384. doi: 10.3390/cancers13102384

Figure 1.

Figure 1

Commonly seen Alternative Lengthening of Telomeres positive (ALT+) cancers and their prognoses relative to their Telomerase positive (TEL+) counterparts.